 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || mosapride SR (DWJ1252) / Daewoong Pharma
Clinical, Journal: Efficacy and Safety of DWJ1252 Compared With Gasmotin Treatment: Once Met 3 Times Tablets. (Pubmed Central) - Jan 1, 2021
No abstract available
- || mosapride SR (DWJ1252) / Daewoong Pharma
Clinical, Journal: Efficacy and safety of DWJ1252 compared with Gasmotin® in the treatment of functional dyspepsia: a multicenter, randomized, double-blind, active-controlled study. (Pubmed Central) - Aug 15, 2020
Adverse events were similar in the 2 groups, and there were no serious adverse events. In patients with FD, DWJ1252 once daily is as effective as Gasmotin® thrice daily, with a similar safety profile.
- ||||| mosapride SR (DWJ1252) / Daewoong Pharma
Trial completion: Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (clinicaltrials.gov) - Jun 26, 2019
P3, N=124, Completed, Sponsor: Daewoong Pharmaceutical Co. LTD.
In patients with FD, DWJ1252 once daily is as effective as Gasmotin® thrice daily, with a similar safety profile. Recruiting --> Completed
- ||||| mosapride SR (DWJ1252) / Daewoong Pharma
Trial completion: Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (clinicaltrials.gov) - Jun 26, 2019
P3, N=124, Completed, Sponsor: Daewoong Pharmaceutical Co. LTD.
Recruiting --> Completed Recruiting --> Completed
- |||||||||| mosapride SR (DWJ1252) / Daewoong Pharma
New P3 trial: Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2) (clinicaltrials.gov) - Jun 12, 2017
P3, N=124, Recruiting, Sponsor: Daewoong Pharmaceutical Co. LTD.
- |||||||||| mosapride SR (DWJ1252) / Daewoong Pharma
New P3 trial: Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (clinicaltrials.gov) - Jan 18, 2017
P3, N=124, Recruiting, Sponsor: Daewoong Pharmaceutical Co. LTD.